Jubilant Ingrevia delivers 14-quarter high revenue in Q4 FY26 as margins strengthen across biz

The company highlighted continued demand strength and pricing resilience despite global disruptions

HealthTech future will be defined by partnerships grounded in trust: Dr. Sabine Kapasi, CEO, Enira Consulting and Founder of ROPAN Healthcare

India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time

Annora Pharma expands partnership with AltiusHub to strengthen AI-driven serialization

Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets

Aarti Drugs posts steady FY26 growth & sharp Q4 rebound despite margin pressure

Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge

Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels

Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%

US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya

Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%

FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies

Caplin Steriles receives USFDA approval for generic foscarnet sodium injection

Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months

Strides Pharma reports Rs. 2,489.7 crore revenue during FY26, 2% YoY growth

Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore

Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority

The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026